Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intellia Thera CS
(NQ:
NTLA
)
23.95
+0.95 (+4.13%)
Streaming Delayed Price
Updated: 1:56 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Intellia Thera CS
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review
January 14, 2022
A rebound from Monday's lows faded, with the key indexes all down for the week.
Via
Investor's Business Daily
If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today
January 13, 2022
Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 32.37% on an annualized basis. Buying $1,000 In NTLA: 5 years ago, an investor could have...
Via
Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
January 13, 2022
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?
Via
Investor's Business Daily
Pfizer Makes Foray Into CRISPR, Inking $1.35 Billion Deal With Beam Therapeutics
January 10, 2022
The companies hope to cure diseases of the liver, muscle and central nervous system.
Via
Investor's Business Daily
Intellia Therapeutics & UiPath Elliott Wave Analysis
October 09, 2021
US Stocks NTLA &PATH technical analysis, Elliott Wave forecast & trading.
Via
Talk Markets
Stock Trading: Intellia Therapeutics Inc & Zillow Technical Analysis
October 02, 2021
Intellia and Zillow technical analysis, Elliott Wave forecast.
Via
Talk Markets
Where Intellia Therapeutics Stands With Analysts
September 24, 2021
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed t...
Via
Benzinga
What 4 Analyst Ratings Have To Say About Intellia Therapeutics
January 07, 2022
Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 05, 2022
Gainers SomaLogic (NASDAQ:SLGC) shares mo...
Via
Benzinga
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
December 22, 2021
2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.
Via
InvestorPlace
36 Stocks Moving In Tuesday's Mid-Day Session
December 07, 2021
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories....
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
January 07, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:
Via
Benzinga
54 Biggest Movers From Yesterday
December 08, 2021
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and...
Via
Benzinga
Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?
November 21, 2021
CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.
Via
The Motley Fool
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
Looking for Growth in Small and Mid Cap Life Science Stocks
November 15, 2021
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.
Via
Talk Markets
Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript
November 06, 2021
NTLA earnings call for the period ending October 3, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
EVP And Chief Medical Officer Of Intellia Therapeutics Trades $340K In Company Stock
October 18, 2021
David Lebwohl, EVP And Chief Medical Officer at Intellia Therapeutics (NASDAQ:NTLA), made a large buy and sell of company shares on October 14, according to a new SEC filing. What...
Via
Benzinga
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
2 Gene-Editing Stocks to Have on Your Radar Right Now
October 17, 2021
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
Via
The Motley Fool
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
October 15, 2021
A key gene-editing readout had Cathie Wood shuffling her portfolio.
Via
The Motley Fool
Exposures
Product Safety
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
October 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
October 08, 2021
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6...
Via
Benzinga
Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients
October 06, 2021
The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study of NTLA-2002...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021
October 05, 2021
Upgrades Wolfe Research upgraded the previous rating for PACCAR Inc (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
October 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
September 24, 2021
Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ:
Via
Benzinga
Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients
September 16, 2021
The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 16, 2021
Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The company's market cap stands at $152.7 million. Phio...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.